Investigation of formulation variables and excipient interaction on the production of niosomes

AAPS PharmSciTech

Volumn 13, Issue 3, 2012, Pages 826-835

  Sezgin Bayindir, Zerrin ^a   Yuksel, Nilufer ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

drug delivery systems; drug release; multiple regression; niosomes; paclitaxel

Indexed keywords

CHOLESTEROL; DICETYL PHOSPHATE; NIOSOME; PACLITAXEL; SORBITAN PALMITATE;

ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; IN VITRO STUDY; MULTIPLE REGRESSION; PARTICLE SIZE; PRIORITY JOURNAL; THERMAL ANALYSIS; X RAY DIFFRACTION; ZETA POTENTIAL;

CHEMISTRY, PHARMACEUTICAL; DRUG INTERACTIONS; EXCIPIENTS; LIPOSOMES; PACLITAXEL;

EID: 84866103663     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9805-4     Document Type: Article

References (31)

1. Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target. 2009;17(9):671-89.
2. Annakula D, Errabelli MR, Jukanti R, Bandari S, Veerareddy PR. Provesicular drug delivery systems: an overview and appraisal. Arch Appl Sci Res. 2010;2(4):135-46.
3. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172:33-70.
4. Mukherjee B, Patra B, Layek B, Mukherjee A. Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study. Int J Nanomedicine. 2007;2(2):213-25.
5. Biju SS, Sushama T, Mishra PR, Khar RK. Vesicular systems: an overview. Indian J Pharm Sci. 2006;68(2):141-53.
6. Elaine M, Liversidge M, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008;36:43-8.
7. Sweetman SC, et al. Martindale: the complete drug reference 2007. 35th ed. London: The Pharmaceutical Press; 2007. p. 685-7.
8. Straubinger RM, Sharma A, Sharma US, Balasubramanian SV. Pharmacology and antitumor effect of novel paclitaxel formulations taxane anticancer agents. Am Chem Soc. 1995;8:111-23.
9. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int J Pharm. 1998;172:1-15.
10. Miele E, Spinelli GP, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99-105.
11. Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci. 2010;99(4):2049-60.
12. Sezgin Z, Yuksel N, Baykara T. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur J Pharm Biopharm. 2006;64(3):261-8.
13. Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech. 2008;9(3):740-7.
14. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release. 2007;120(3):169-77.
15. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338(1-2):317-26.
16. Hu FQ, Ren GF, Yuan H, Du YZ, Zeng S. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf B Biointerfaces. 2006;50(2):97-103.
17. Ruckmani K, Sankar V. Formulation and optimization of Zidavudine niosomes. AAPS PharmSciTech. 2010;11(3):1119 -1127. doi: 10.1208/s12249-010- 9480-2.
18. Abdelkader H, Ismail S, Kamal A, Alany RG. Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. J Pharm Sci. 2011;100:1833-46.
19. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003;66:1207-18.
20. Carafa M, Santucci E, Alhaique F, Coviello T, Murtas E, Riccieri FM, Lucania G, Torrisi MR. Preparation and properties of new unilamellar non-ionic:ionic surfactant vesicles. Int J Pharm. 1998;160:51-9.
21. Varshosaz J, Pardakhty A, Hajhashemi VI, Najafabadi AR. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv. 2003;10(4):251-62.
22. Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm. 2008;353(1-2):233-42.
23. Liggins RT, Hunter WL, Burt M. Solid-state characterization of paclitaxel. J Pharm Sci. 1997;86(12):1458-63.
24. Junior JA, Kawano Y, Petri DFS. Thin films of carbohydrate based surfactants and carboxy methylcellulose acetate butyrate mixtures: morphology and thermal behavior. Mater Sci Eng C. 2009;29(2):420-5.
25. Yadav K, Yadav D, Saroha K, Nanda S, Mathur P, Syan N. Proniosomal gel: a provesicular approach for transdermal drug delivery. Der Pharmacia Lettre. 2010;2(4):189-98.
26. Honary SE, Ebrahimi P, Tabbakhian M, Zahir F. Formulation and characterization of doxorubicin nanovesicles. J Vac Sci Technol B Microelectron Nanometer Struct. 2009;27(3):1573-7.
27. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, Puglisi G. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325:172-9.
28. Dong Y, Feng SS. Poly(d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(30):6068-76.
29. Zhang Z, Feng SS. Self-assembled nanoparticles of poly(lactide)-vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm. 2006;324(2):191-8.
30. Nasr M, Mansour S, Mortada ND, Elshamy AA. Vesicular aceclofenac systems: a comparative study between liposomes and niosomes. J Microencapsul. 2008;25(7):499-512.
31. Yuksel N, Baykara M, Shrinzade H, Suzen S. Investigation of triacetineffect on indomethacin release from poly(methyl methacrylate) microspheres: evaluation of interactions using FT-IR and NMR spectroscopies. Int J Pharm. 2011;404:102-9.